Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 29, 1999 - Issue 5
26
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Biotransformation of the antipsychotic agent, mazapertine, in dog-mass spectral characterization and identification of metabolites

, , , &
Pages 453-466 | Published online: 22 Sep 2008

References

  • BUCLIN, T., STUCKI, R., JAQUET -MUELLER, F., MUNAFO, A., BAULDAUF, C., BRUNNER -FERBER, F. and BIOLLAZ, J., 1993a, Tolerability and psychopharmacological profile of the novel antipsychotic mazapertine (RWJ-37796) in healthy volunteers. Clinical Pharmacology and Therapeutics, 53,179 (abstract, 94th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics).
  • BUCLIN, T., STUCKI, R., JAQUET -MUELLER, F., MUNAFO, A., BAULDAUF, C., BRUNNER -FERBER, F., PIQUET, V. and BIOLLAZ, J., 1993b, Tolerance, psychopharmacological profile and pharmaco-kinetics of a new neuroleptic, mazapertine (RWJ-37796), in healthy volunteers. Schweizerische Medizinische Wochenschrift, 123 (16, S50), 39.
  • GISCLON, L. G. and CURTIN, C. R., 1993, The effect of food on the bioavailability (BA) of a new antipsychotic drug (RWJ-37796). Pharmaceutical Research, 10, S-398 (abstract, AAPS 8th Annual Meeting).
  • REITZ, A. B., BENNET, D. J., BLUM, P. S., CODD, E. E., MARYANOFF, C. A., ORTEGON, M. E., RENZI, M. J., SCOTT, M. K., SHANK, R. P. and VAUGHT, J. L., 1994, A new arylpiperazine antipsychotic with high D2/D3/5-H TiA/aiA-adrenergic affinity and a low potential for extrapyramidal effects. Journal of Medicinal Chemistry, 37, 1060–1062.
  • REITZ, A. B., McDoNNELL, M. E., BAXTER, E. W., CODD, E. E. and Wu, W. N., 1997, The synthesis and evaluation of the major metabolites of mazapertine. Bioorgank and Medicinal Chemistry Letters, 7, 1927–1930.
  • WONG, D. F., YUNG, B. C. K., GIORGIANNI, J. A., CHEN, C., CHAN, B., GISCLON, L. G., DANNALS R. F., RAVERT, H. T., SHAYA, E., CURTIN, C. R. and OFFORD, S. J., 1993, D2 Dopamine receptor occupancy as a function of intravenous rising dose of mazapertine (RWJ-37796) in normal living human brain. journal of Nuclear Medicine, 34,109 (abstract, 40th Annual Meeting of the Society of Nuclear Medicine).
  • Wu, W. N., McKowN, L. A., GAUTHIER, A. D., JoNEs, W. J. and TAKACS, A. R., 1994a, Metabolism and excretion of the antipsychotic agent, RWJ-3776 in rats. Pharmaceutical Research, 11, S-336 (abstract, the 9th AAPS Annual Meeting).
  • Wu, W. N., McKowN, L. A., JoNEs, W. J., TAKACS, A. R., REITZ, A. Band MCDONNELL, M. E., 1994b, Mass spectral characterization and identification of the metabolites of the antipsychotic agent, RWJ-37796, in dogs. Proceedings of the 42nd ASMS Conference on Mass Spectrometry, 344.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.